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1 The direct cardiac electrophysiological and antifibrillatory actions of tedisamil (KC-8857) were
studied in rabbit isolated hearts.
2 Tedisamil (1, 3, and 10 gM), prolonged the ventricular effective refractory period (VRP) from
120±18 ms (baseline) to 155 + 19, 171+20, and 205+14 ms, respectively. Three groups of isolated
hearts (n = 6 each) were used to test the antifibrillatory action of tedisamil. Hearts were perfused with
1.25 Mm pinacidil, a KATP channel activator. Hearts were subjected to hypoxia for 12 min followed by
40 min of reoxygenation. Ventricular fibrillation (VF) developed during hypoxia and reoxygenation in
both the control and 1 gM tedisamil-treated groups (5/6 and 4/6, respectively). Tedisamil (3 gM) reduced
the incidence of VF (0/6, P= 0.007 vs. control).
3 In a separate group of hearts, VF was initiated by electrical stimulation. The administration of 0.3 ml
of 10 mM tedisamil, via the aortic cannula, terminated VF in all hearts, converting them to normal sinus
rhythm.
4 Tedisamil (3 gM) reversed pinacidil-induced negative inotropic effects in rabbit isolated atrial muscle
which were equilibrated under normoxia, as well as in atrial muscle subjected to hypoxia and
reoxygenation.
5 The results demonstrate a direct antifibrillatory action of tedisamil in vitro. The mechanism
responsible for the observed effects may involve modulation by tedisamil of the cardiac ATP-regulated
potassium channel, in addition to its antagonism of IK and Ith.
Keywords: Class III antiarrhythmics; arrhythmia; KATp-regulated channel blocker; chemical defibrillation; myocardial
ischaemia; potassium currents
Introduction
In experimental studies and clinical trials, Class III antiar-
rhythmic agents have been demonstrated to be more effective
than other classes of antiarrhythmic drugs in preventing lethal
ventricular arrhythmias (Lynch et al., 1992; Lucchesi et al.,
1993; Gilman et al., 1994). By prolonging the ventricular ef-
fective refractory period and action potential duration, Class
III antiarrhythmic agents abolish re-entrant impulses and
prevent or terminate ventricular fibrillation (Sanguinetti, 1992;
Uprichard & Lucchesi, 1994). Currently available Class III
drugs (amiodarone and sotalol) not only block K+ currents in
the heart, but also act on other ion channels and/or receptors
causing unwanted effects (Sanguinetti, 1992). Recently devel-
oped Class III antiarrhymthmic agents, such as sematilide,
MS-551, E-4031, and dofetilide (UK 68,798), selectively block
the delayed rectifier K+ current (IK), but the reverse use-
dependence properties of these agents could limit their ther-
apeutic utilily (Hondeghem & Snyders, 1990; Baskin et al.,
1991; Nakaya et al., 1993; Sager et al., 1993). Thus, the search
for new compounds in this class as well as compounds tar-
geting other types of K+ channels remains an important area
of investigation.
Recent studies have shown that blockade of the transient
outward current (Ito) and inward rectifier K+ current (I , both
of which are involved in the repolarization of the action po-
tential (Carmeliet, 1992a), contribute to antiarrhythmic and
antifibrillatory actions (Beatch et al., 1991; Rees & Curtis,
1993). Tedisamil (KC-8857; 3,7-di-(cyclopropyhmethyl)-9, 9-
tetramethylene-3, 7-diazabicyclo [3.3.1]-nonanedihydrochlor-
ide) is a bradycardic agent and a putative Ito blocker. In rat
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isolated ventricular mycocytes, tedisamil, at low concentra-
tions (1-20 gM), selectively suppressed IO and prolonged ac-
tion potential duration (Dukes & Morad, 1989; Dukes et al.,
1990). Tedisamil had no significant effects on the inward rec-
tifier K+ current, or inward Ca2" current in rat or guinea-pig
ventricular myocytes and blocked the Na' current only at
concentrations above 20 uM (Dukes & Morad, 1989; Dukes et
al., 1990). In both conscious and anaesthetized rats, tedisamil
(i.v.) lengthened the ventricular effective refractory period,
action potential duration, QT interval, and reduced the in-
cidence of ventricular fibrillation induced by coronary artery
ligation. In addition, tedisamil caused bradycardia and in-
creased systemic blood pressure (Howard et al., 1989; Beatch
et al., 1990; 1991). The antifibrillatory effects and associated
electrophysiological actions of tedisamil have been examined in
vivo (Beatch et al., 1990; 1991) as well as in rat isolated hearts
(Tsuchihashi & Curtis, 1991), a species in which I,, is the
predominant repolarization current (Josephson et al., 1984;
Dukes & Morad, 1989).
The present study explores the electrophysiological prop-
erties of tedisamil, and more importantly, demonstrates the
antifibrillatory effects of tedisamil in a species possessing both
functional Ito and IK in the ventricular myocardium (Giles &
Imiazumi 1988; Hiraoka & Kawano, 1989; Carmeliet, 1993; de
Lorenzi et al., 1994). We used the rabbit isolated heart model
in the present study to determine the direct, concentration-
dependent effects of tedisamil on the ventricular effective re-
fractory period and atrioventricular node conduction because,
like the rat, the rabbit myocardium contains prominent,
functional I,, and IKE In addition, the effects of tedisamil were
examined in two models: prevention of hypoxia/reoxygena-
tion/pinacidil-induced ventricular fibrillation and reversal of
electrically-induced ventricular fibrillation.
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Methods
The studies were performed in accordance with the guidelines
of the 'University of Michigan Committee on the Use and Care
of Animals'. The animal care and use programme conforms to
the standards in 'The Guide for the Care and Use of La-
boratory Animals', DHEW Publ. No. (NIH) 86-23.
Langendorif perfused isolated heart preparation
New Zealand white rabbits (2.1-2.5 kg) were randomized to
different experimental groups. All rabbits were killed by cer-
vical dislocation. The hearts were removed rapidly and pre-
pared for perfusion by the Langendorff method using a
modified Krebs-Henseleit buffer. Coronary artery perfusion
was maintained with the use of a roller pump adjusted to
produce a mean coronary artery perfusion pressure of
40 + 5 mmHg (20 +2 ml min-') maintained throughout the
experimental protocol. The hearts were paced at a frequency of
10-20% above their intrinsic sinoatrial rate. The pacing sti-
mulus was provided by a Grass SD5 (Grass Instrument
Company, Quincy, MA, U.S.A.) pulse generator and applied
to the right atrium via bipolar electrodes. The pacing stimulus
was set at 10% above threshold voltage and a pulse duration of
4 ms. A cannula with a latex balloon at its distal end was
inserted through the left atrium, across the mitral valve and
placed in the left ventricle. The proximal end of the cannula
was connected to a pressure transducer for recording left
ventricular systolic and end-diastolic pressures. The balloon
was expanded with distilled water to establish a ventricular
end-diastolic pressure of 5 mmHg. The volume in the in-
traventricular balloon was maintained constant throughout
the course of each experiment. A polyethylene cannula was
placed in the left ventricle to vent the chamber. A thermistor
probe (Tele-thermometer, Yellow Springs Instrument Co.
Yellow Springs, OH, U.S.A.) was inserted in the left ventricle
to monitor the temperature of the heart. The electrogram was
recorded by electrodes attached to the aorta and apex of the
heart. A pressure transducer was connected to a side arm of the
aortic cannula to monitor the coronary artery perfusion
pressure (CPP). The left ventricular pressure (LVP), the first
derivative of the left ventricular pressure (±dP/dt), electro-
gram and coronary perfusion pressure (CPP) were recorded
with a Grass Model 7 polygraph (Grass Instrument Company,
Quincy, MA, U.S.A.).
The hearts were equilibrated for 30 to 40 min before each
experiment and perfused without recirculating the buffer. The
temperature of the buffer was maintained constant at 370C.
The buffer was prepared daily and adjusted to pH 7.4. The
perfusion medium was circulated through an 'artificial lung'
consisting of 6 metres of medical grade, gas permeable tubing
(Silastic, Dow Corning Corp, Midland, MI, U.S.A.) placed in
a water-heated chamber. The chamber was gassed con-
tinuously with 95% 02/5% CO2 to generate a P02 of ap-
proximately 500 mmHg in the perfusion medium.
Experimental protocols
Protocol I: Electrophysiology The effects of tedisamil on the
ventricular excitation threshold voltage (VET), ventricular
refractory period (VRP) and atrioventricular conduction were
determined in 9 isolated hearts perfused with a modified
Krebs-Henseleit buffer to the following composition (mmol
1-'): NaCl 117, KCI 4.0, CaCl2.H20 2.4, MgCl2.6H20 1.2,
NaHCO3 25, KH2PO4 1.1, glucose 5.0, monosodium L-gluta-
mate 5.0, and sodium pyruvate 2.0. The final concentration of
K+ in the perfusion medium was 5.1 mm. A miniature bipolar
plunge electrode (INAPRES, Norwich, NY, U.S.A.) was at-
tached to the right ventricular outflow tract (RVOT) for de-
livery of the S2 ventricular stimulus from a Grass S8800 square
wave stimulator and stimulus isolation unit (SIU5; Grass In-
strument Company, Quincy, MA, U.S.A.). The S2 stimulus,
with a duration of 4 ms, was triggered 250 ms after the 'R
wave' of the electrogram. The excitation threshold voltage was
defined as the minimum voltage required to elicit a propagated
ventricular impulse. The refractory period determined in the
region ofRVOT is defined as the longest R-wave to S2 stimulus
interval that failed to elicit a propagated ventricular complex
at 1.5 times threshold voltage. The P-R interval was de-
termined from the electrogram recording. After a 60 min
period of equilibration, the hearts were perfused with buffer
containing 0.1, 1, 3 or 10 iM tedisamil. Electrophysiological
parameters were determined 15 min after exposure to each
concentration of tedisamil. Figure la illustrates the experi-
mental protocol.
Protocol 2: Hypoxia/reoxygenation and pinacidil-induced ven-
tricular fibrillation (Figure 1) A total of 22 rabbit isolated
hearts were used in this portion of the experiment, from which
4 hearts were excluded before entering the protocol due to
technical failures. Eighteen hearts were randomly allocated to
three experimental groups: control, n = 6; tedisamil (1 tUM),
n = 6; tedisamil (3 gM), n = 6. After 30 to 40 min of equilibra-
tion, the isolated hearts were perfused with buffer containing
drug-vehicle solution (control) or tedisamil (1 gM and 3 MM)
for 10 min followed by pinacidil (1.25 AM), an ATP-regulated
K+ (KATP) channel opener, added to the buffer. Five min after
the addition of pinacidil, the hearts were subjected to 12 min of
perfusion under hypoxic conditions by changing the gas mix-
ture in the 'artificial lung' to 95%N2/5%CO2. At the end of the
hypoxic perfusion period, normoxic perfusion of the heart was
reinstituted (reoxygenation) and maintained for 40 min. The
cardiac electrogram, coronary perfusion pressure and left
ventricular function were monitored continuously. The end-
point of the experiment was defined as the occurrence of sus-
tained ventricular fibrillation during hypoxia and/or reox-
ygenation. The composition of the buffer perfusate in this
protocol had the following composition (in mmol I`): NaCl
117, KCl 1.4, CaCl2.H20 2.4, MgCl2.6H20 1.2, NaHCO3 25,
KH2PO4 1.1, glucose 5.0, monosodium L-glutamate 5.0 and
sodium pyruvate 2.0. The final concentration of K+ in the
perfusion medium was 2.5 mM.
Protocol 3: Tedisamil and chemical defibrillation To de-
termine whether tedisamil could terminate sustained ven-
tricular fibrillation, a separate group of 9 hearts were
examined. Hearts in this protocol were perfused with a mod-
ified Krebs-Henseleit buffer with the same composition as
described in protocol 1. Sustained ventricular fibrillation was
induced by a train of electrical stimuli delivered through a
(1) Electrophysiology
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Figure 1 Schematic experimental protocols used in the rabbit
isolated heart study. Protocol 1 was used to examine the direct
electrophysiological effects of tedisamil at various concentrations. All
electrophysiological parameters were recorded 15 min after the
exposure to each concentration of tedisamil. Protocol 2 was used
to determine the ability of tedisamil to prevent hypoxia-induced
ventricular fibrillation in the presence of pinacidil.
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miniature bipolar plunge electrode (INAPRES, Norwich, NY,
U.S.A.) secured over the right ventricular outflow tract
(RVOT) for delivery of the S2 ventricular stimulus from a
Grass S8800 square wave stimulator and stimulus isolation
unit (SIU5; Astro-Med Inc., West Warwick, RI, U.S.A.). The
S2 stimulus duration was 4 ms and was triggered after the 'R
wave' of the electrogram. Hearts received a train of stimuli
delivered to the region of the RVOT (S2, S3, S4-instead of a
single impulse) until ventricular fibrillation occurred. Typical
ventricular fibrillation induction parameters included a pulse
level of 7- IV, a pulse delay of 100-150 ms, a pulse interval
of 90-100 ms, a pulse duration of 4.0 ms, and a train duration
of 200- 500 ms. Ventricular fibrillation was sustained for 30 s,
at which time 0.3 ml of vehicle (buffer) was injected through a
sideport of the aortic cannula. After an additional 30 s had
elapsed, either vehicle or tedisamil (0.3 ml or 0.6 ml of 1 mM
drug, or 0.3 ml of 10 mM drug) was administered. The time
from the second injection to reversal to normal sinus rhythm
was recorded.
Rabbit isolated atrial muscle preparation Rabbit atria (1 cm
long, 3 mm wide and 2 mm thick) were excised from rabbit
isolated hearts and quickly placed in oxygenated, 370C, mod-
ified Krebs-Henseleit buffer of the same composition as de-
scribed in protocol 1. The muscle preparations were in contact
with a pair of platinum electrodes and fixed at one end in a
spring-loaded clamp. The other end of the tissue was attached
to a calibrated force displacement transducer (Grass Instru-
ment Co., Quincy MA, U.S.A., Model FT.03C). The electrical
signal from the displacement transducer was amplified and
recorded with a Grass Polygraph. The atrial tissue was sti-
mulated with a Grass S88 square wave generator at a fre-
quency of 1.5 Hz, a pulse duration of 4 ms at twice the
minimum threshold voltage. The tissue was preloaded with 4 g
of tension by adjusting the height of the force displacement
transducer.
The isolated muscle preparations were allowed to equili-
brate for 60 min under normoxia (95% 02/5% C02) or 20 min
under hypoxia (95% N2/5% CO2) followed by 40 min reox-
ygenation (n= 10 in each group), during which time the
bathing media was replaced three times. The experimental
protocol was begun after a steady state of isometric force de-
velopment had been achieved. The concentration-response
relationship for the negative inotropic action of pinacidil was
established by a cumulative increase in the concentration of
pinacidil in the bathing media. There was a 5 min interval
between each increment in drug concentration to allow a new
steady state response to develop. To determine if tedisamil
could reverse pinacidil-induced negative inotropy, tedisamil
(3 gM) was added to the bathing media after the final con-
centration of pinacidil had been achieved in the bath. There-
after, the recovery of muscle tension was monitored for 5 min.
The change in isometric tension was determined and expressed
as a percentage of the pre-drug, baseline value.
Materials
Tedisamil hydrochloride (KC-8857; 3,7-di-(cyclopro-
pylmethyl) - 9,9 - tetramethylene -3,7-diazabicyclo[3.3. l]nonane
dihydrochloride, Figure 2) was supplied by Solvay Pharma-
N0N
Figure 2 Chemical structure of tedisamil (KC-8857) (3,7-di-
(cyclopropylmethyl)-9,9-tetramethylene-3,7-diazabicyclo[3.3. lInonane
dihydrochloride).
ceuticals (Germany). All other materials were purchased from
Sigma Chemical Co. (St. Louis, MO, U.S.A.) unless otherwise
specified.
Data analysis
The data are expressed as mean + s.e. mean. The difference in
the incidence of ventricular fibrillation among groups was
analyzed by Fisher's Exact test. ANOVA (factorial) was used
for comparisons between groups at specific time points. AN-
OVA (repeated measures), followed by a Fisher's protected
least significant difference (PSLD) post hoc test was used for
comparisons over time within groups. Statistical significance
was established as a probability of <0.05.
Results
Electrophysiological action of tedisamil
After 60 min of equilibration, hearts were perfused with buffer
containing 0.1, 1, 3 and 10 gM tedisamil. Electrophysiological
parameters were determined 15 min after exposure to each
concentration of tedisamil (Figure 1). Figure 3 is an example of
S2 stimulation and induced PVCs during the determination of
VET and VRP. Tedisamil, at a concentration of 1, 3 and
10 gM, prolonged VRP from a mean baseline value of
120+18 ms to 155+19 ms, 171+20 ms, and 205+14 ms, re-
spectively (Figure 4). The VET was increased by 1, 3 and
10 gM tedisamil, but reached statistical significance at 3 gM
compared to baseline value (Figure 4). A significant pro-
longation of P-R interval was observed after 1, 3 and 10 gM
tedisamil treatment (from a mean baseline value of 76 +4 ms
to 86+ 5 ms, 103 + 4 ms and 139 + 13 ms, respectively, Figure
4). A 2:1 A-V conduction block or atrioventricular dis-
sociation occurred in 6 out of 7 hearts treated with 10 gM
tedisamil. Figure 5 is an original recording from one experi-
ment depicting the concentration-dependent prolongation of
P-R interval and 2: 1 A-V blockade at a tedisamil concentra-
tion of 10 MM.
Prevention of ventricular fibrillation
One group of hearts was used as a control group while the
other two groups were exposed to 1 gM or 3 Mm tedisamil
added to the perfusion medium 10 min before the addition of
pinacidil. There was a high incidence of ventricular fibrillation
during hypoxia and reoxygenation in both the control group
and in the group of hearts treated with 1 gM tedisamil (5/6 and
4/6, respectively). When the concentration of tedisamil was
increased to 3 gM, the incidence of ventricular fibrillation was
reduced significantly (0/6, P= 0.007 vs. control group, by
Fisher's Exact Test; Figure 6 and Table 1). Figure 6 shows the




2000 ms 400 ms 100 ms
Figure 3 An original recording during the determination of the
ventricular excitation threshold (VET) and ventricular effective
refractory period (VRP) in the rabbit isolated heart. The premature
ventricular complexes (PVCs) induced by programmed electrical
stimulation (PES) are indicated. Cycle length, 400ms; S1S2 interval =
169ms; threshold voltage = 3.4V.
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Figure 5 An example of the progressive increase of P-R interval by
tedisamil in Protocol 1. The complete atrioventricular (A-V) block
occurred after 1OMm tedisamil. The rabbit isolated hearts were paced





(3 gM)Baseline 0.1 FM 1 iM 3jM
Tedisamil
10 gIM
Time at the onset of
ventricular fibrillation









Baseline 0.1 FiM 1 jiM 3 jM 10 gM
Tedisamil
Figure 4 Tedisamil, at 1, 3, and lOyM, prolonged the ventricular
effective refractory period (VRP) (c) and P-R interval (a) in the
rabbit isolated heart (n=9). The increase of ventricular excitation
threshold (VET) (b) was significant in the presence of 3 gM tedisamil.
*PJO.05 and **P<0.01, compared with the baseline value by paired
t test in each panel. All the values were determined 15 min after each
concentration of tedisamil.
Time (min)
Figure 6 Time course of development of ventricular fibrillation in
the hypoxic/reoxygenated rabbit isolated heart. Three groups of
hearts (n=6 in each group) were perfused with buffer containing
pinacidil (1.25pM) for 5min, then subjected to hypoxia for 12min
followed by 40min of reoxygenation. Two groups of hearts were
exposed to tedisamil (1 and 3yM) 10min before the addition of
pinacidil in the perfusion medium. Ventricular fibrillation occurred in
5 of 6 hearts from the control group (without tedisamil). Tedisamil,
at 3Mm, significantly reduced the incidence of ventricular fibrillation
compared with that of the control group. Each symbol represents an
individual isolated heart.
Table 1 Antifibrillatory action of tedisamil in rabbit
isolated hearts under hypoxia/reoxygenation and pinacidil
challenge









Chemical defibrillation with tedisamil
Vehicle administration (0.3 or 0.6 ml) did not change the status
(frequency or duration) of ventricular fibrillation and sponta-
neous reversal to sinus rhythm did not occur in any of the
hearts (Figure 7). Tedisamil (0.3 or 0.6 ml of a 1 mM solution)
did not terminate ventricular fibrillation, although the cycle
length was prolonged, e.g. the frequency of the fibrillatory
waves was reduced (data not shown). However, administration
of 0.3 ml of a 10 mM tedisamil solution terminated ventricular
fibrillation in each of the 5 hearts (P = 0.008 vs. vehicle group
by Fisher's Exact Test; Figure 7). The frequency of the fi-
brillatory waves was reduced immediately after the drug was
introduced and normal sinus rhythm was restored within
98 + 47 s. The electrically induced ventricular fibrillation was
converted to ventricular tachycardia in two hearts several
seconds after tedisamil, and proceeded to normal sinus rhythm
within minutes. Figure 8 is a representative tracing from a
heart that was successfully defibrillated after the administra-
tion of tedisamil.
Effects of tedisamil on cardiac function
During the study of antifibrillatory effects in the three groups



































Termination of ventricular fibrillation conversion
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Figure 7 Time course for chemical defibrillation by tedisamil of
electrically-induced ventricular fibrillation in the rabbit isolated heart.
Ventricular fibrillation (VF) was induced in two sets of hearts (at a)
one of which received a bolus injection of vehicle 30 (b) and 60 s (c)
after induction of VF (n=4). The other group of hearts received a
bolus injection of vehicle 30s (b) after induction of VF and 0.3 ml of
10mM tedisamil 60s (c) after induction of VF. Hearts receiving
vehicle only did not revert to normal sinus rhythm whereas 100% of
hearts receiving tedisamil were converted to normal sinus rhythm (P
= 0.008 compared to vehicle by Fisher's Exact Test).
continuously. All hearts were paced electrically from the right
atrium at a frequency of 20-30% above the intrinsic sinus
rate. Heart rate is expressed as the total number of ventricular
complexes and includes both the paced ventricular complexes
as well as those depolarizations arising spontaneously. During
the latter phase of hypoxia the heart rate was reduced in each
of three groups even though atrial electrical pacing was
maintained. The observed bradycardia suggests the develop-
ment of atrioventricular block due to hypoxia. Hearts treated
with 1 gM tedisamil demonstrated less bradycardia during
hypoxia, compared to 3 gM tedisamil-treated hearts (Table 2).
Normal atrioventricular conduction returned upon reox-
ygenation in all groups. There was no difference in heart rate
among groups at respective time-points throughout the ex-
perimental procedure (Table 2).
Tedisamil, in a concentration-dependent manner, increased
the coronary perfusion pressure (CPP) from a mean baseline
value of 43+3 mmHg to 54+4 mmHg at 1 gM and from
37 + 3 mmHg to 50+ 3 mmHg at 3 gIM after 10 min of ex-
posure (Table 2). Both LVDP and + dP/dt decreased to the
same extent during hypoxia followed by a partial return upon
reoxygenation in all experimental groups. Due to the devel-
opment of ventricular fibrillation, very few hearts remained in
the control group and 1 gM tedisamil-treated groups during
reoxygenation, thus precluding statistical analysis of the data
towards the latter part of the reoxygenated period. Tedisamil
did not change any cardiac functional parameters, such as
LVDP, left ventricular end-diastolic pressure (LVEDP) and
left ventricular + dP/dt throughout the experiment (Tables 3
and 4).
Rabbit isolated atrial muscle
Reversal of the pinacidil-induced negative inotropic effect The
amplitude of isometric contractile force was approximately
62% of baseline after exposure to the final concentration of
pinacidil (10'- M) in atrial tissue equilibrated under normoxia.
The subsequent addition of tedisamil (3 gM) to the bathing
medium in the continued presence of pinacidil (10-4 M) re-
sulted in a reversal of the pinacidil-induced negative inotropic
action. The isometric-contractile force of the atrial muscle
preparations recovered and achieved 86% of pre-drug baseline
values after 5 min of 3 gM tedisamil exposure (Figure 9a).
Similarly, contractile force in atrial tissue was approximately
67% of baseline after treatment with the final concentration of
pinacidil in atrial tissue equilibrated under hypoxia/reox-
ygenation. The isometric-contractile force of the atrial muscle
recovered to approximtely 86% of baseline contractions after
treatment with 3 gM tedisamil (Figure 9b).
Electrogram Left ventricular pressure
E°[ I >1~~~(ml00.
Baseline
E o k E
Ventricular fibrillation (5 s)
1 min 50 s post tedisamil injection (0.3 ml of 10 mM)
2 m~~~~100.> 2 __ _ _ _ _ _
13 min 30 s post tedisamil injection (0.3 ml of 10 mM)
400 ms
Figure 8 An example of the chemical defibrillatory effects of
tedisamil in the rabbit isolated heart. Sustained ventricular fibrillation
(VF) was elicited by a train of electrical stimuli applied to the RVOT.
Tedisamil (0.3ml of 10mM) was administered to the heart through
the cannulated aorta while the coronary vessels were perfused
continuously with oxygenated buffer. The cycle length of the
fibrillatory waves was prolonged progressively and ventricular
fibrillation was converted to normal sinus rhythm after 1 min and
50s exposure to tedisamil. Cardiac function recovered to the pre-
fibrillation state 13min after drug administration.
Discussion
Unlike calcium channel blockers and f-adrenoceptor antago-
nists, tedisamil does not depress ventricular contractile func-
tion while reducing heart rate (Thormann et al., 1993). The
blockade of K+ outward currents and subsequent prolonga-
tion of repolarization in the sinoatrial pacemaker cells ac-
counts for the bradycardic action of tedisamil (Dukes &
Morad, 1992). The extent of QTc prolongation caused by te-
disamil has been shown to be species-dependent. Tedisamil
caused a significant increase in the QTc and/or prolongation of
the action potential duration in rat myocardium (Beatch et al.,
1990). In contrast, limited QTc prolongation was observed in
other species, such as dogs, guinea-pigs, rabbits, and pigs
(Buschmann et al., 1989). This difference may be due to the
role of different K+ channels in repolarization of the cardiac
tissue in a variety of species. The antiarrhythmic and anti-
fibrillatory effects of tedisamil have been reported mainly in rat
heart models (Beatch et al., 1991; Adaikan et al., 1992; Bril et
al., 1993), a species in which It. is the predominant outward
repolarizing current in ventricular myocardium. In our in-
vestigation, the direct electrophysiological and antifibrillatory
effects of tedisamil were investigated in rabbit isolated hearts.
Two independent models were used to assess the anti-
fibrillatory action of tedisamil.
In conscious and anaesthetized rats, Adaikan et al. (1992)
and Beatch et al. (1991) reported that tedisamil (0.5-
4 mg kg-', i.v.) dose-dependently lengthened the effective re-
fractory period, the duration of epicardial intracellular action
potential, and the QTc interval. Bril et al. (1993) reported a
similar observation and suggested that specific blockade of Ito
was responsible for the apparent Class III action of tedisamil,
since the IKr (rapidly activating component of IK) blocker, E-
4031, did not change QTc interval in a similar anaesthetized rat
model. Tedisamil was also shown to prolong the effective re-
fractory period and QTc interval in anaesthetized dogs (Wal-
lace et al., 1995). In our investigation, the blockade of both It.
and IK by tedisamil may be operative and responsible for the
observed increases in the ventricular refractory period (Figure
4).
1265
L. Chi et a! Effects of tedisamil in vitro



































Tedisamil Pinacidil Hypoxia Reoxygenation
















aP<0.05 vs. control, ANOVA; bp<0.05 vs. baseline; CP<0.05 vs. 10 min tedisamil; dp<0.05 vs. 5 min pinacidil, Fisher's PLSD.
Values in parentheses represent numbers of hearts from which mean ± s.e. were calculated. tPinacidil concentration= 1.25 gM.
Table 3 Effects of tedisamil on left ventricular pressure in rabbit isolated hearts
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aP<0.05 vs. control, ANOVA; bp<0.05 vs. baseline; CP<0.05 vs. 10 min tedisamil; dp<0.05 vs. 5 min pinacidil, Fisher's PLSD.
Values in parentheses represent numbers of hearts from which mean ± s.e. were calculated. tPinacidil concentration= 1.25 gM.
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455 + 73(5)b"' 620 + 120(5)b"d
aP<0.05 vs. control, ANOVA; bp<0.05 vs. baseline; 'P<0.05 vs. 10 min tedisamil; dp<0.05 vs. 5 min pinacidil, Fisher's PLSD.
Values in parentheses represent numbers of hearts from which mean + s.e. were calculated. tPinacidil concentration = 1.25 MM.
When rabbit isolated hearts were perfused in the presence of
pinacidil, a high incidence of spontaneous and sustained ven-
tricular fibrillation occurred during hypoxic perfusion or dur-
ing reoxygenation, which was significantly reduced in the
presence of 3,M tedisamil (Figure 6). Shortening of action
potential duration, reduction of refractory period and initia-
tion of re-entry are precursors to the onset of ventricular fi-
brillation (Chi et al., 1993; Fagbemi et al., 1993). Several K+
channel blockers, such as glibenclamide, E-403 1, clofilium
(Friedrichs et al., 1994) and ibutilide (Friedrichs et al., 1993),
effectively prevented the development of ventricular fibrillation
in this model. In vivo studies reveal that tedisamil prevents
regional ischaemia- and reperfusion-induced ventricular fi-
brillation in anaesthetized and conscious rats (Beatch et al.,
1991; Adaikan et al., 1992; Bril et al., 1993). It was proposed
that tedisamil increased refractoriness, which resulted in an
extension of path lengths such that the multiple re-entry cir-
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Figure 9 (a) Represents the recovery of atrial muscle contractile
force after the addition of tedisamil to the pinacidil (10-4M)-
depressed rabbit atrial muscle preparation (n= 10) which was
equilibrated under normoxic conditions. Tedisamil (31iM) reversed
the negative inotropic effect of pinacidil in the rabbit isolated atrial
muscle preparation which is represented in the figure by the shaded
area. *P<0.05 compared to baseline using a paired t test 1P<0.05
compared to 3 x 10-4M pinacidil using a paired t test. (b) Depicts
a pinacidil-induced (1 x 10-5M to 3 x 10-4M) concentration-depen-
dent negative inotropic effect on rabbit isolated atrial tissue (n= 10)
which was equilibrated during 20min of hypoxia followed by 40 min
of reoxygenation. Tedisamil (3pM) restored approximately 85% of
pre-pinacidil isometric contraction, which is represented in the figure
by the shaded area. *P<0.05 compared to baseline using a paired t
test. tPsO.O5 compared to 3 x 10-4M pinacidil using a paired t test.
ventricular fibrillation could not occur (Adaikan et al., 1992).
In rat isolated hearts, the antifibrillatory effect of tedisamil was
limited to reducing the duration of ventricular fibrillation and
had no influence on the incidence of ventricular fibrillation
elicited by regional ischaemia and reperfusion (Tsuchihashi &
Curtis, 1991). The results in the present study may suggest that
blockade of more than one type of K+ channel may be more
effective in mediating antiarrhythmic activity. An additive or
synergistic effect might exist between K+ channel subtypes
under the influence of certain compounds as suggested by the
findings of Bril et al. (1993) who observed that the combina-
tion of tedisamil with E-4031 in the anaesthetized rat exerted a
greater antifibrillatory effect than with tedisamil alone.
The inhibition of the ATP-regulated potassium channel
may contribute to the antifibrillatory action of tedisamil in the
pinacidil-treated hypoxic/reoxygenated heart. In the present
experimental model, activation of the KATP channel by pina-
cidil serves an important role in the initiation of ventricular
fibrillation (Chi et al., 1993; Fagbemi et al., 1993). Pinacidil
selectively enhances the KATP current (Arena & Kass, 1989)
and shortens the action potential duration, thus facilitating re-
entry in myocardial tissue (Di Diego & Antzelevitch, 1993;
Coromilas et al., 1994). Hypoxia and reoxygenation lead to the
development of an appropriate substrate for re-entrant ar-
rhythmias facilitated further by a decrease in myocardial cel-
lular ATP content which potentiates the action of pinacidil on
the ventricular ATP-regulated potassium channel (Chi et al.,
1993). Inside-out patch clamp studies from rat ventricular cells
demonstrate that tedisamil (20 gM) significantly decreased
KATP channel activity (Faivre & Bril, 1992). Bril et al. (1993)
observed that tedisamil and E-4031 increased the QTc more
during ischaemia than during the pre-ischaemic period, sug-
gesting that tedisamil and E-4031 may have an effect on a
current involved during acute ischaemia, such as the KATP
current. The ability of tedisamil to reverse the pinacidil-in-
duced negative inotropic effect in rabbit isolated atrial tissue
further supports our hypothesis that tedisamil inhibits the
KATP channel in myocardial tissue (Figure 9).
The chemical defibrillatory effect of tedisamil was demon-
strated in non-ischaemic rabbit isolated hearts in which ven-
tricular fibrillation was induced by electrical stimulation
(Figure 7). Tedisamil restored normal sinus rhythm under
conditions in which the myocardial tissue was perfused under
normoxic conditions. Thus, one would assume that cellular
ATP content was normal and that the KATp-dependent channel
would be closed (Kakei et al., 1985). Our observation is con-
sistent with the ability of tedisamil to terminate ventricular
fibrillation in rat isolated hearts (Tsuchihashi & Curtis, 1991).
In the latter studies, tedisamil (3 gM) reduced the duration of
VF in regional ischaemic/reperfused hearts, but was unable to
prevent the induction of VF. Chemical defibrillation in this
model had been observed with other compounds possessing
Class III activity (Friedrichs et al., 1993; 1994). The mode and
kinetics of action of tedisamil in the conversion of VF is dif-
ferent from that of ibutilide and clofilium. The frequency of the
fibrillatory waves decreased immediately upon exposure of the
heart to tedisamil and slowed progressively over time until VF
was converted to normal sinus rhythm. The antiarrhythmic
action of tedisamil in the normoxic heart may be related to its
ability to inhibit the two potassium currents responsible for
cardiac action potential repolarization under normoxic con-
ditions, i.e. the transient outward current (Ito) (Dukes &
Morad, 1989) and the delayed rectifier current (IK) (Dukes et
al., 1990). ATP-regulated potassium channels are present in
cardiac muscle cells (Noma, 1993), and would be closed and
non-functional under conditions of normoxic perfusion thus
making unimportant any action of tedisamil upon the IKAw,_
However, we cannot exclude the possibility that partial sodium
block by tedisamil might also contribute to threshold eleva-
tion, thereby slowing intramyocardial conduction. In contrast
to other studies, tedisamil at 3 gM significantly increased the
ventricular excitation threshold and prolonged the P-R inter-
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other ion channels (Figure 4b and c). There have been reports
of sodium channel modulation by tedisamil. In single rat
ventricular myocytes, the suppression of the sodium current by
tedisamil occurred only at a concentration greater than 20 uM
(Dukes & Morad, 1989; Dukes et al., 1990).
Both positive and negative inotropic actions of tedisamil
have been reported in in vivo and in vitro investigations as well
as an improvement in cardiac function during myocardial
ischaemia. These effects of tedisamil on cardiac function,
however, were attributed primarily to its bradycardic action
and subsequent favourable influence on the oxygen supply/
demand balance in the ischaemic hearts (Grohs et al., 1989;
Duchosal & Opie, 1992; Raberger et al., 1992). The brady-
cardic effect of tedisamil (under normoxia) was not observed in
our investigation since the heart was paced throughout the
experimental protocol (Table 2). Therefore, the antifibrillatory
effect of tedisamil is due to its direct electrophysiological ac-
tion, independent of any influence on the cardiac function and/
or the extent of pathophysiological conditions. An increase in
arterial resistance has been observed with other K+ channel
antagonists. Studies (Bray & Quast, 1992; Kreye et al., 1992)
indicate that tedisamil and glibenclamide directly modulate
mechanical tension in rat and rabbit isolated vascular smooth
muscle by affecting K+ channels. An increase of blood pres-
sure or vascular resistance has been observed with tedisamil
experimentally in vivo as well as clinically (Beatch et al., 1991;
Mitrovic et al., 1992; Thormann et al., 1993).
In conclusion, tedisamil possesses an effective anti-
fibrillatory and chemical defibrillatory action in two experi-
mental models. The effects are independent of its potential
bradycardic action and influence on cardiac function. The
Class III antiarrhythmic activity, i.e., increase of refractori-
ness, and prevention and/or termination of re-entry appear to
be the primary mechanisms for its antifibrillatory effects, al-
though effects on the other channels including sodium and
calcium cannot be entirely excluded. The nature of the ex-
perimental model indicates that blockade of the ATP-regu-
lated potassium channel is important in mediating the
electrophysiologic effects of tedisamil. However, the inhibition
of the I,. and the Ik may likewise contribute to the beneficial
effects. Tedisamil may be unique when compared to other
Class III antiarrhythmic agents (E-4031 (Sanguinetti & Jur-
kiewicz, 1990) and Dofetilide (Carmeliet, 1992b)) that selec-
tively block IKr current. Additional studies in more elaborate in
vivo models are needed to determine fully its potential in the
prevention of lethal arrhythmias.
The work in this study was supported by a grant from the National
Institutes of Health, Heart, Lung and Blood Institute, Grant No.
HL05806-34 and an educational gift from Solvay Pharma Deutsch-
land GmbH.
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